HEPA Hepion Pharmaceuticals Inc
Price (delayed)
$0.478
Market cap
$66,522
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$219
Enterprise value
$793,121
The Company's lead drug candidate, CRV431, is a potent inhibitor of cyclophilins, which are involved in many disease processes. CRV431 is currently in clinical-phase development for the treatment of NASH,
Highlights
HEPA's EPS has soared by 65% YoY and by 32% QoQ
HEPA's net income is up by 49% year-on-year and by 20% since the previous quarter
Hepion Pharmaceuticals's equity has plunged by 111% from the previous quarter and by 103% YoY
Hepion Pharmaceuticals's quick ratio has plunged by 74% YoY and by 65% from the previous quarter
Key stats
What are the main financial stats of HEPA
Market
Valuations
Earnings
Shares outstanding
139,167
Market cap
$66,522
Enterprise value
$793,121
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$28.55M
Net income
-$22.7M
EBIT
-$25.65M
EBITDA
-$25.61M
Free cash flow
-$26.07M
Per share
Balance sheet
Liquidity
EPS
-$219
EPS diluted
-$219
Free cash flow per share
-$193.97
Book value per share
-$3.51
Revenue per share
$0
TBVPS
$27.65
Total assets
$3.72M
Total liabilities
$4.12M
Debt
$2.22M
Equity
-$406,685
Working capital
$814,328
Debt to equity
-5.47
Current ratio
1.3
Quick ratio
0.77
Net debt/EBITDA
-0.03
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-207.3%
Return on equity
-505.7%
Return on invested capital
-2,921.5%
Return on capital employed
-2,567.3%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
HEPA stock price
How has the Hepion Pharmaceuticals stock price performed over time
Intraday
-1.44%
1 week
-30.22%
1 month
-92.41%
1 year
-99.58%
YTD
-97.97%
QTD
11.19%
Financial performance
How have Hepion Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$28.55M
Net income
-$22.7M
Gross margin
N/A
Net margin
N/A
HEPA's net income is up by 49% year-on-year and by 20% since the previous quarter
The operating income has grown by 40% YoY and by 18% from the previous quarter
Growth
What is Hepion Pharmaceuticals's growth rate over time
Valuation
What is Hepion Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
HEPA's EPS has soared by 65% YoY and by 32% QoQ
Hepion Pharmaceuticals's equity has plunged by 111% from the previous quarter and by 103% YoY
Efficiency
How efficient is Hepion Pharmaceuticals business performance
The return on assets has dropped by 86% year-on-year and by 19% since the previous quarter
Hepion Pharmaceuticals's ROIC has soared by 69% from the previous quarter
Hepion Pharmaceuticals's ROE has plunged by 54% from the previous quarter
Dividends
What is HEPA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for HEPA.
Financial health
How did Hepion Pharmaceuticals financials performed over time
The total assets is 10% less than the total liabilities
The total assets has plunged by 85% YoY and by 38% from the previous quarter
The current ratio has dropped by 77% since the previous quarter and by 61% year-on-year
Hepion Pharmaceuticals's equity has plunged by 111% from the previous quarter and by 103% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.